Peter Godolphin is a medical statistician based in the meta-analysis programme at MRC CTU at UCL. He joined UCL in Autumn 2019, after previously working as a medical statistician at Nottingham Clinical Trials Unit at the University of Nottingham. He works as a statistician on the STOPCAP M1 programme (http://www.stopcapm1.org/), that aims to speed up the evaluation of therapies for metastatic hormone-sensitive prostate cancer. In April 2021, he began an National Institute for Health Research (NIHR) Development and Skills Enhancement Award in meta-analysis. 

Peter completed his PhD in Clinical Trials Research at the University of Nottingham in 2019 after previously completing a MSc in Medical Statistics (University of Leicester, 2015) and a BSc in Mathematics (University of Birmingham, 2014). In 2014, he was appointed on a NIHR Research Methods Fellowship at Nottingham Clinical Trials Unit to contribute to both methodological and empirical research in clinical trials. In 2016, he was awarded funding to continue research in clinical trials methodology at Nottingham Clinical Trials Unit through a NIHR Doctoral Research Fellowship. In this, he evaluated the costs and benefits of adjudicating outcomes in stroke trials.